Provide feedbackProvide feedback

Home :: Ophthalmology

Ohr Pharmaceutical wins fast track designation for wet AMD product candidate

Monday, May 14 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration granted Ohr Pharmaceutical Inc.'s squalamine eye drops fast track status for the treatment of wet age-related macular degeneration (AMD). Squalamine inhibits vascular endothelial growth factor and other angiogenic growth factors, such as platelet-derived growth factor, which Ohr said has been identified as an additional key target for the treatment of wet AMD. The compound is expected to enter Phase II testing in the third quarter. Ohr recently presented...

The Food and Drug Administration granted Ohr Pharmaceutical Inc.'s squalamine eye drops fast track status for the treatment of wet age-related macular degeneration (AMD).

Squalamine inhibits vascular endothelial growth factor and other angiogenic growth factors, such as platelet-derived growth factor, which Ohr said has been identified as an additional key target for the treatment of wet AMD. The compound is expected to enter Phase II testing in the third quarter.

Ohr recently presented findings from a biodistribution and safety study of its squalamine eye drops at the 2012 annual meeting of the Association for Research in Vision and Ophthalmology. Trial data indicated the "potential therapeutic value of the squalamine eye drop program in treating wet AMD and ophthalmic neovascular disorders," according to Ohr.

Irach Taraporewala, Ohr's chief executive officer, said squalamine eye drops could provide "tremendous benefit" to patients who use Genentech Inc.'s Lucentis (ranibizumab) or Regeneron Pharmaceuticals Inc.'s Eylea (aflibercept), both of which are administered via intravitreal injection.

Latest News

Bayer, Regeneron enter into agreement with Santen to co-promote Eylea in Japan Verusmed

Tuesday, May 08 2012 | Comments
Evidence Grade 0 What's This?

Bayer HealthCare AG and Regeneron Pharmaceuticals Inc. entered into an agreement with Santen Pharmaceutical Co. Ltd. to co-promote the ophthalmic drug Eylea (aflibercept) in Japan.

Under the terms of the agreement, Bayer's Japanese subsidiary, Bayer Yakuhin Ltd., will co-promote...



Quark extends Pfizer agreement to develop investigational compound in glaucoma indication Verusmed

Thursday, May 03 2012 | Comments
Evidence Grade 0 What's This?

Quark Pharmaceuticals Inc. amended an existing exclusive licensing agreement with Pfizer Inc. to include the development of PF-655, an investigational small interfering RNA therapeutic product, as a treatment for glaucoma.

The amendment will make it possible for Quark to conduct a Phase IIa trial to evaluate the ability of PF-655 to enhance visual function in patients with moderate or advanced...



Lucentis, Avastin show comparable efficacy in treating wet AMD; Avastin yields higher SAE rate Verusmed

Wednesday, May 02 2012 | Comments
Evidence Grade 0 What's This?

Two-year results from a head-to-head trial of Genentech Inc.'s Avastin (bevacizumab) and Lucentis (ranibizumab) indicate that the drugs have comparable efficacy profiles as treatments for neovascular (wet) age-related macular degeneration (AMD), according to data published in the May 1 issue of the journal Ophthalmology.

In light of these findings, the

ThromboGenics refiles BLA for eye disorder treatment Verusmed

Tuesday, April 17 2012 | Comments
Evidence Grade 0 What's This?

ThromboGenics NV resubmitted a Biologics License Application (BLA) to the Food and Drug Administration for ocriplasmin 2.5 mg/mL, an intravitreal injection, for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole, a progressive condition that can lead to significant visual distortion, deterioration in vision and in some cases central blindness if left...





  1. No articles have been read
  1. No articles have been emailed
Videos